Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
82.0%
-
Total 13F principal
-
$449,991,048
-
Principal change
-
-$6,697,452
-
Total reported market value
-
$373,710,879
-
Number of holders
-
41
-
Value change
-
-$3,654,814
-
Number of buys
-
15
-
Number of sells
-
16
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q1 2021
As of 31 Mar 2021,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
41 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$449,991,048
in principal (par value) of the bond.
The largest 10 bondholders included
Silver Point Capital L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Kohlberg Kravis Roberts & Co. L.P., UBS ASSET MANAGEMENT AMERICAS INC, AMERIPRISE FINANCIAL INC, DeepCurrents Investment Group LLC, ADVENT CAPITAL MANAGEMENT /DE/, OAKTREE CAPITAL MANAGEMENT LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, and Birch Grove Capital LP.
This page lists
41
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.